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Presentation
An infant girl is born by vaginal delivery at 40 weeks’ gestation to a gravida 4, para 2012 
mother after maternal induction of labor for intrauterine growth restriction (IUGR). Family 
history is notable for a father and first-child born small for gestational age. Prenatal 
ultrasonography results at 28 weeks’ gestation are normal; fetal weight at that time was in 
the 43rd percentile for gestational age. Prenatal laboratory findings include negative group B 
Streptococcus, Gonorrhea, Chlamydia, rubella immune, hepatitis B surface antigen 
nonreactive, and human immunodeficiency virus nonreactive. Her mother has no prior 
medical conditions; denies substance use, including tobacco smoke and cocaine; and reports 
not taking anymedications other than prenatal vitamins. The infant’s Apgar scores are 9 and 
9 at 1 and 5 minutes after birth, respectively, requiring only routine care at delivery. Her 
initial examination findings are remarkable for depressed fontanelles, and she has no 
dysmorphic features. Her birth weight is 1,875 g (<3 percentile), length is less than 3 
percentile, head circumference is less than 3 percentile, and her Ballard score is 38 
(equivalent to 39 weeks’ gestation) on admission.
Cord gas analysis results are within the normal range. Glucose levels at ages 5 and 6 hours 
are 41 and 46 mg/dL (2.3 and 2.6 mmol/L), respectively. After breastfeeding, her glucose 
level improves to 77 mg/dL (4.3 mmol/L) at 8 hours. Her total bilirubin level at 29 hours is 
4.7 mg/dL (80.4 µmol/L). Urine toxicology test results are negative. A quantitative IgM 
level is within normal limits, and urine cytomegalovirus and viral culture results are 
negative. Placental pathologic findings are consistent with a third trimester placenta and 
reveal no evidence of chorioamnionitis. Head ultrasonography findings on day 2 are normal 
with no signs of calcifications. The genetics department is consulted given the unclear origin 
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of her IUGR, and a microarray analysis is performed on day 3. Despite an increase in her 
feeding volumes and fortifying her formula, she has daily weight loss, worsening depression 
of her fontanelles, and skin tenting. By day 10, she tolerates daily oral feeds of 145 kcal/kg, 
has a mean hourly urine output of 7.5 mL/kg, and is 12% below birth weight. Because of 
polyuria and continued weight loss despite increased caloric intake, blood chemical analyses 
are performed, which reveal the diagnosis.
Discussion
Diagnosis
Blood chemical analysis findings are notable for the following: glucose, 1,039 mg/dL (57.7 
mmol/L); potassium, 5.2 mEq/L (5.2 mmol/L); bicarbonate, 15 mEq/L (15 mmol/L); anion 
gap, 19; blood urea nitrogen, 27 mg/dL (9.6 mmol/L); and creatinine, 0.8 mg/dL (71 
µmol/L). A urinalysis reveals a specific gravity of 1.030, a glucose level of 3+, and a ketone 
level of 1+. The C-peptide level is low at less than 0.10 ng/mL (<0.03 nmol/L), and the β-
hydroxybutyrate level is normal at 0.52 mg/dL (50 µmol/L). These laboratory results reveal 
hyperglycemia, anion gap metabolic acidosis, and prerenal acute kidney injury. She is 
diagnosed as having neonatal diabetes mellitus, classified as nothing-by-mouth status, and 
given an insulin infusion at 0.05 U/kg per hour. Half normal saline and 5 mEq/kg of 
potassium chloride fluids are administered to give total daily volumes of 200 mL/kg to 
correct dehydration from hyperosmotic diuresis. Glucose levels are checked every 3 hours. 
Dextrose fluids (glucose infusion rate, 7 mg/kg per minute) are administered 3 hours later 
when blood glucose levels start decreasing too rapidly at a rate of greater than 150 mg/dL 
per hour. To limit the rate of decrease of the glucose and, later, to maintain glucose levels of 
100 to 200 mg/dL (5.6–11.1 mmol/L), insulin is adjusted to 0.02 to 0.1 U/kg per hour, and 
dextrose fluids are titrated. When her anion gap closes and feeds are resumed, the insulin 
rate is increased by 0.01 U/kg per hour during feeds to maintain glucose goals.
Abdominal ultrasonography is performed and reveals no signs of pancreatic agenesis. Given 
her paucity of subcutaneous fat, she requires continuous intravenous insulin until 3 weeks 
after birth when she is able to transition to long-acting subcutaneous insulin. A 
chromosomal microarray identifies microduplication of chromosome 6 at 6q24, suggesting a 
diagnosis of transient neonatal diabetes. At 2 months, she exceeds the fifth weight percentile 
and is successfully weaned off insulin.
The Condition
Neonatal diabetes mellitus is a rare metabolic condition that has an incidence of 
approximately 1 in 300,000 live births. It is thought to be a nonautoimmune process that 
results from altered expression of imprinted genes on chromosome 6, causing delayed 
maturation of pancreatic islets and β-cells. Because insulin normally functions as a fetal 
growth factor, IUGR is thought to be a result of insulin deficiency from lack of fetal 
production and failure of maternal insulin to cross the placental barrier. Diagnosis has been 
defined as hyperglycemia occurring within the first month after birth, lasts for at least 2 
weeks, and requires insulin treatment.
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Most patients present with low birth weight, failure to thrive, dehydration, low or 
undetectable C-peptide levels, and negative islet cell antibodies. It can present as transient 
neonatal diabetes mellitus (TNDM) or permanent neonatal diabetes mellitus (PNDM), 
depending on the duration of insulin dependence. TNDM occurs more frequently than 
PNDM (55% vs 45%) and is associated with IUGR and younger age at presentation. PNDM 
is more often associated with ketoacidosis. Patients with TNDM are on average able to stop 
insulin therapy at approximately age 3 months. Among infants with TNDM, relapse of 
diabetes during adolescence or adulthood occurs in 40% of patients and presents with 
common features of type 2 diabetes. Because recurrence of diabetes can occur after a period 
of remission, TNDM may be considered a prediabetic state; it is believed to be from a 
permanent β-cell defect with variable expression during different stages of growth. Roughly 
half of PNDM cases are associated with mutations in the potassium channel, and some may 
respond to sulfonylureas. Most of the mutations are de novo, and mutational analysis of 
chromosome 6 may serve as a tool to identify which patients likely have TNDM vs PNDM.
There are currently no universal guidelines for neonatal diabetes management. Treatment of 
neonatal diabetes is difficult given the paucity of subcutaneous fat in low-birth-weight 
infants; therefore, continuous intravenous insulin is the accepted first-line therapy, typically 
at a rate of 0.02 to 0.1 units/kg per hour. The long-term prognosis is good, and cognitive 
development is expected to be normal.
Lessons for the Clinician
• In an infant with IUGR, dehydration, and poor weight gain despite adequate caloric 
intake, reevaluation may reveal conditions such as neonatal diabetes mellitus.
• Treatment of neonatal diabetes mellitus includes continuous intravenous insulin 
infusion, intravenous hydration, and close monitoring of glucose and electrolytes.
• The diagnosis of transient neonatal diabetes mellitus has long-term implications, 
such as relapses of hyperglycemia and development of type 2 diabetes mellitus in 
adolescence.
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American Board of Pediatrics Neonatal-Perinatal Content Specifications
• Know the causes, including genetic and autogenic disorders, of neonatal 
hyperglycemia, including transient diabetes mellitus.
• Know the clinical and laboratory features and approach to therapy of neonatal 
hyperglycemia, including transient diabetes mellitus.
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